Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
posted on
Mar 01, 2024 01:23PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"I don't see a deal as the market is sayng otherwise , until then we wait it out or we exit "
Hard to exit NXT when zen's been doing PP's for around a buck but for us to exit we're looking at 10-15 pennys because of this crap market were on hence folks hanging on but getting more & more frustrated as each year/decade passes. Almost the same with RVX ,some are in at one - two bucks , some higher so waiting & stewing has become the option even tho painful.
Believe the mental health wouldn't be an issue but when you put your trust in someone but then finally realize you've been mislead, some have said lied to for years this is what transpires.
GLTA